References
- Minos E, Barry RJ, Southworth S, et al. Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment. Orphanet J Rare Dis. 2016; 11(1):61. Published May 12, 2016. doi:https://doi.org/10.1186/s13023-016-0429-8.
- Levinson RD, Brezin A, Rothova A, Accorinti M, Holland GN. Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference. Am J Ophthalmol. 2006;141(1):185–187. doi:https://doi.org/10.1016/j.ajo.2005.08.025.
- McGonagle D, Aydin SZ, Gül A, Mahr A, Direskeneli H. ‘MHC-I-opathy’-unified concept for spondyloarthritis and Behçet disease. Nat Rev Rheumatol. 2015;11(12):731–740. doi:https://doi.org/10.1038/nrrheum.2015.147.
- Kuiper J, Rothova A, de Boer J, Radstake T. The immunopathogenesis of birdshot chorioretinopathy; a bird of many feathers. Prog Retin Eye Res. 2015;44:99–110. doi:https://doi.org/10.1016/j.preteyeres.2014.11.003.
- Shah KH, Levinson RD, Yu F, et al. Birdshot chorioretinopathy. Surv Ophthalmol. 2005;50(6):519–541.doi:https://doi.org/10.1016/j.survophthal.2005.08.004.
- Rothova A, Berendschot TT, Probst K, van Kooij B, Baarsma GS. Birdshot chorioretinopathy: long-term manifestations and visual prognosis. Ophthalmology. 2004;111(5):954–959. doi:https://doi.org/10.1016/j.ophtha.2003.09.031.
- Priem HA, Oosterhuis JA. Birdshot chorioretinopathy: clinical characteristics and evolution. Br J Ophthalmol. 1988;72(9):646–659. doi:https://doi.org/10.1136/bjo.72.9.646.
- Levinson RD, Monnet D, Yu F, Holland GN, Gutierrez P, Brezin AP. Longitudinal cohort study of patients with birdshot chorioretinopathy. V. Quality of life at baseline. Am J Ophthalmol. 2009;147(2):346–350.e2. doi:https://doi.org/10.1016/j.ajo.2008.08.011.
- Kuiper JJ, Missotten T, Baarsma SG, Rothova A. Vision-related quality of life in patients with birdshot chorioretinopathy. Acta Ophthalmol. 2013;91(4):e329–e331. doi:https://doi.org/10.1111/aos.12054.
- Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7–22. doi:https://doi.org/10.1002/hec.3564.
- Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol. 2001;119(7):1050–1058.doi:https://doi.org/10.1001/archopht.119.7.1050.
- Brown GC, Brown MM, Sharma S, et al. The burden of age-related macular degeneration: a value-based medicine analysis. Trans Am Ophthalmol Soc. 2005;103:173–186.
- Shamdas M, Bassilious K, Murray PI. Health-related quality of life in patients with uveitis. Br J Ophthalmol. 2019;103(9):1284–1288. doi:https://doi.org/10.1136/bjophthalmol-2018-312882.
- Niemeyer KM, Gonzales JA, Doan T, Browne EN, Rao MM, Acharya NR. Time trade-off utility values in noninfectious uveitis. Am J Ophthalmol. 2019;208:47–55. doi:https://doi.org/10.1016/j.ajo.2019.06.005.
- Nussenblatt RB, Palestine AG, Chan -C-C, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467–471. doi:https://doi.org/10.1016/S0161-6420(85)34001-0.
- Mahroo OAR, Hobby AE, Yonova EH, et al. Towards rapid assessment of retinal function in clinic: comparison of implicit times of photopic flicker electroretinogram responses recorded using a conventional and a portable system in patients with Birdshot chorioretinopathy. Invest Ophthalmol Vis Sci. 2016;57(12):3594.
- Bleichrodt H. A new explanation for the difference between time trade-off utilities and standard gamble utilities. Health Econ. 2002;11(5):447‐456. doi:https://doi.org/10.1002/hec.688.
- van Osch SM, Wakker PP, van den Hout WB, Stiggelbout AM. Correcting biases in standard gamble and time tradeoff utilities. Med Decis Making. 2004;24(5):511‐517. doi:https://doi.org/10.1177/0272989X04268955.
- Matza LS, Boye KS, Feeny DH, et al. The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation. Eur J Health Econ. 2016;17(8):979–990.doi:https://doi.org/10.1007/s10198-015-0740-7.
- Au Eong KG, Chan EW, Luo N, et al. Validity of EuroQOL-5D, time trade-off, and standard gamble for age-related macular degeneration in the Singapore population. Eye (Lond). 2012;26(3):379–388.doi:https://doi.org/10.1038/eye.2011.218.
- Brown MM, Brown GC, Sharma S, Shah G. Utility values and diabetic retinopathy. Am J Ophthalmol. 1999;128(3):324–330. doi:https://doi.org/10.1016/s0002-9394(99)00146-4.
- Heintz E, Wiréhn AB, Peebo BB, Rosenqvist U, Levin LÅ. QALY weights for diabetic retinopathy–a comparison of health state valuations with HUI-3, EQ-5D, EQ-VAS, and TTO. Value Health. 2012;15(3):475–484. doi:https://doi.org/10.1016/j.jval.2011.11.031.
- Gupta V, Srinivasan G, Mei SS, Gazzard G, Sihota R, Kapoor KS. Utility values among glaucoma patients: an impact on the quality of life. Br J Ophthalmol. 2005;89(10):1241–1244. doi:https://doi.org/10.1136/bjo.2005.068858.
- Gothwal VK, Bagga DK, Rao HL, et al. Is utility-based quality of life in adults affected by glaucoma? Invest Ophthalmol Vis Sci. 2014; 55(3):1361–1369. Published 2014 Mar 6. doi:https://doi.org/10.1167/iovs.13-13729.
- Bozzani FM, Alavi Y, Jofre-Bonet M, Kuper H. A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma. BMC Ophthalmol. 2012;12(1):43. doi:https://doi.org/10.1186/1471-2415-12-43.Published 2012 Aug 21.
- Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110(7):1412–1419. doi:https://doi.org/10.1016/S0161-6420(03)00462-7.
- Buchholz P, Steeds CS, Stern LS, et al. Utility assessment to measure the impact of dry eye disease. Ocul Surf. 2006;4(3):155–161.doi:https://doi.org/10.1016/s1542-0124(12)70043-5.
- Zacks DN, Samson CM, Loewenstein J, Foster CS. Electroretinograms as an indicator of disease activity in birdshot retinochoroidopathy. Graefes Arch Clin Exp Ophthalmol. 2002;240(8):601–607. doi:https://doi.org/10.1007/s00417-002-0506-7.
- Holder GE, Robson AG, Pavesio C, Graham EM. Electrophysiological characterisation and monitoring in the management of birdshot chorioretinopathy. Br J Ophthalmol. 2005;89(6):709–718. doi:https://doi.org/10.1136/bjo.2004.047837.
- Sobrin L, Lam BL, Liu M, Feuer WJ, Davis JL. Electroretinographic monitoring in birdshot chorioretinopathy. Am J Ophthalmol. 2005;140(1):52–64. doi:https://doi.org/10.1016/j.ajo.2005.01.053.
- Dean S, Mathers JM, Calvert M, et al. “The patient is speaking”: discovering the patient voice in ophthalmology. Br J Ophthalmol. 2017;101(6):700–708.doi:https://doi.org/10.1136/bjophthalmol-2016-309955.
- Barry JA, Folkard A, Denniston AK, Moran E, Ayliffe W. Development and validation of quality-of-life questionnaires for birdshot chorioretinopathy. Ophthalmology. 2014;121(7):1488–9.e2. doi:https://doi.org/10.1016/j.ophtha.2014.01.007.
- Moots RJ, Fortune F, Situnayake D. The Behçet’s centres of excellence. Rheumatology (Oxford). 2018;57(4):594–595. doi:https://doi.org/10.1093/rheumatology/kex037.